Atorvastatin therapy and antioxidant status correction in patients with metabolic syndrome
https://doi.org/10.15829/1560-4071-2013-3-51-55
Abstract
Aim. To study the changes in antioxidant status and glucose-insulin homeostasis among atorvastatin-treated patients with metabolic syndrome and to investigate the potential of coenzyme Q10 for the correction of these changes.
Material and methods. The study included 44 patients with metabolic syndrome (MS). For one year, the first group (n=21) received atorvastatin, while the second group (n=23) received atorvastatin and coenzyme Q10. The examination included the assessment of lipid and carbohydrate metabolism, lipid peroxidation system, and antioxidant status parameters.
Results. Atorvastatin suppressed antioxidant system and increased insulin resistance in patients with MS. The combination of atorvastatin and coenzyme Q10 increased antioxidant defence levels, prevented a statinnduced increase in lipid peroxidation, and did not affect carbohydrate metabolism parameters in MS patients.
Conclusion. The combination of atorvastatin and coenzyme Q10 demonstrated lipid-lowering effects, optimised lipid peroxidation processes, increased antioxidant defence levels, and minimised negative statininduced effects on glucose and insulin metabolism in MS patients.
About the Authors
N. S. Yubitskaya
Vladivostok Branch, Far Eastern Research Centre of Respiratory Physiology and Pathology, Siberian Branch, Russian Academy of Medical Sciences, Research Institute of Medical Climatology and Rehabilitation, Vladivostok, Russia
Russian Federation
Russian Federation
M. V. Antonyuk
Vladivostok Branch, Far Eastern Research Centre of Respiratory Physiology and Pathology, Siberian Branch, Russian Academy of Medical Sciences, Research Institute of Medical Climatology and Rehabilitation, Vladivostok, Russia
Russian Federation
Russian Federation
V. I. Yankova
Vladivostok Branch, Far Eastern Research Centre of Respiratory Physiology and Pathology, Siberian Branch, Russian Academy of Medical Sciences, Research Institute of Medical Climatology and Rehabilitation, Vladivostok, Russia
Russian Federation
Russian Federation
References
1. The metabolic syndrome. Ed. G. E. Roytenberg. Moscow: MED-press-inform, 2007 (Метаболический синдром. Под ред. Г. Е. Ройтенберга. М.: МЕД-пресс-информ; 2007).
2. The Diagnostics and treatment of the metabolic syndrome. The Russian
3. recommendations. Cardiovascular Therapy and Prevention. 2009. 8. (6, Suppl. 2). 28 p. (Диагностика и лечение метаболического синдрома: Российские рекомендации ВНОК (второй пересмотр). Кардиоваскулярная терапия и профилактика 2009. 8 (6). Приложение 2. 28 с.).
4. Mkrtumjan A. M., Birjukova E. V. The basic approach to pharmacotherapy of a metabolic syndrome. Cons med 2006; 8 (5): 54–7. Russian (Мкртумян А. М., Бирюкова Е. В. Основной подход к фармакотерапии метаболического синдрома.Cons Med 2006; 8 (5):54–7).
5. Langs’on P. H., Langs’on A. M. Medical application inhibiting HMG-CoA reductase and accompanying deficiency of coenzyme Q10. The review of the experimental works executed on mammals and the person. Russian medical journal. 2007; 9 (15): 747– 52. Russian (Лангсьон П. Х., Лангсьон А. М. Медицинское применение ГMК-КoA-резуктазы и сопутствующий дефицит коэнзима Q10. Обзор экспериментальных работ, выполненных на млекопитающих и человеке. РМЖ 2007; 9 (15):747–52).
6. Ivanova M. V., Kuharchuk V. V., Konovalova G. G. et al. Effect of inhibitors of beta-hydroxybeta-methylglutaryl coenzyme A reductase and antioxidant vitamins on free radical oxidation of lipids of rat liver. Byulleten” eksperimental’noy biologii i meditsiny 2007, 4:390–3. Russian (Иванова М. В., Кухарчук В. В., Коновалова Г. Г. и др. Влияние ингибиторов бета-гидрокси-бета-метилглутарил-коэнзим А-редуктазы и витаминов-антиоксидантов на свободнорадикальное окисление липидов печени крыс. Бюлл. экспер. биологии и медицины 2007, 4:390–3).
7. Kljuchnikov S. O., Gnetneva E. S. Ubiquinon (Coenzyme Q10). Clinical aspects. Lechawij vrach 2007, 7:86–7. Russian (Ключников С. О., Гнетнева Е. С. Убихинон (коэнзим Q10). Клинические аспекты. Лечащий врач 2007, 7:86–7).
8. Hodgson J. M., Watts G. F., Playford D. A., et al. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 2002, 56 (11):1137–42.
9. Susekov A. V., Gorjakova N. B. Demonstrative base of atorvastatin – the international and domestic researches. Cons med 2008, 10 (11):109–15. Russian (Сусеков А. В., Горякова Н. Б. Доказательная база аторвастатина – международные и отечественные исследования. Cons Med 2008; 10 (11):109–15).
10. Men’shchikova E. B., Lankin V. Z., Zenkov N. K. et al. Oxidative stress. Prooxidants and antioxidants. M.: Slovo, 2006 (Меньщикова Е. Б., Ланкин В. З., Зенков Н. К. и др. Окислительный стресс. Прооксиданты и антиоксиданты. М.: Фирма “Слово”; 2006).
11.
12.
Review
For citations:
Yubitskaya N.S., Antonyuk M.V., Yankova V.I. Atorvastatin therapy and antioxidant status correction in patients with metabolic syndrome. Russian Journal of Cardiology. 2013;(3):51-55. (In Russ.) https://doi.org/10.15829/1560-4071-2013-3-51-55
Views:
1644
Email this article 